Greater than 95% of acute promyelocytic leukemia (APL) cases are associated with the expression of PML-RARa. This chimeric protein has been strongly implicated in APL pathogenesis because of its interactions with growth suppressors (PML), retinoid signaling molecules (RXRa), and nuclear hormone transcriptional co-repressors (N-CoR and SMRT). A small number of variant APL translocations have also been shown to involve rearrangements that fuse RARa to partner genes other than PML, namely PLZF, NPM, and NuMA. We describe the molecular characterization of a t(5;17)(q35;q21) variant translocation involving the NPM gene, identi®ed in a pediatric case of APL. RT ± PCR, cloning, and sequence studies identi®ed NPM as the RARa partner on chromosome 5, and both NPM-RARa and RARa-NPM fusion mRNAs were expressed in this patient. We further explored the eects of the NPM-RARa chimeric protein on the subcellular localization of PML, RXRa, NPM, and PLZF using immuno¯uorescent confocal microscopy. While PML remained localized to its normal 10 ± 20 nuclear bodies, NPM nucleolar localization was disrupted and PLZF expression was upregulated in a microspeckled pattern in patient leukemic bone marrow cells. We also observed nuclear co-localization of NPM, RXRa, and NPM-RARa in these cells. Our data support the hypothesis that while deregulation of both the retinoid signaling pathway and RARa partner proteins are molecular consequences of APL translocations, APL pathogenesis is not dependent on disruption of PML nuclear bodies.
Introduction
For over 40 years acute promyelocytic leukemia (APL) has been recognized as a subtype of acute leukemia because of its morphology and clinical association with fatal coagulopathy (Hillestad, 1957) , as well as its unique association with translocations involving the retinoic acid receptor alpha gene (RARa) (GigueÁ re et al., 1987) . Nearly 100% of APL cases are associated with a t(15;17)(q22;q21) translocation that fuses RARa to the promyelocytic leukemia gene (PML) at chromosome 15q22 (de TheÂ et al., 1990 (de TheÂ et al., , 1991 Alcalay et al., 1991; Goddard et al., 1991; Kakizuka et al., 1991) . The resulting PML-RARa gene is invariably expressed in t(15;17) APL (Castaigne et al., 1992; Grignani et al., 1994) in comparison to the reciprocal RARa-PML gene which is expressed in approximately 80% of cases (Alcalay et al., 1992; Borrow et al., 1992; Grimwade et al., 1996; Li et al., 1997) .
Although the molecular mechanisms of action of PML-RARa are still unclear, it has been shown to exert its transforming eects by sequestering hematopoietic factors like RXRa, PML, and PLZF (Dyck et al., 1994; Weis et al., 1994; Koken et al., 1997; He et al., 1998) ; or by acquiring altered transactivating properties that aect retinoic acid (RA) and PML responsive genes (de TheÂ et al., 1991; Kakizuka et al., 1991) . Much like RARa (Chen and Evans, 1995; Nagy et al., 1997) , PML-RARa retains the ability to recruit the transcriptional co-repressors N-CoR and SMRT to RA responsive genes (Hong et al., 1997) . In contrast to RARa, PML-RARa appears to interact with N-CoR and SMRT to form stable transcriptional repressor complexes under physiological concentrations of RA (Grignani et al., 1998; Guidez et al., 1998; He et al., 1998; Lin et al., 1998) .
PML is a nuclear matrix protein that localizes in the nucleus to 10 ± 20 discreet nuclear bodies or PML oncogenic domains (PODs) (Daniel et al., 1993; Dyck et al., 1994) . In t(15;17) APL cells it has been shown that PML is delocalized, and closely associated with PML-RARa in a dispersed, subcellular pattern (Dyck et al., 1994; Koken et al., 1994; Weis et al., 1994) . The ®nding that t(15;17) cells treated with all trans retinoic acid (atRA) reform PML nuclear bodies resulted in the hypothesis that the disruption of PML nuclear bodies is a key molecular event in APL pathogenesis (Dyck et al., 1994) . Although the cellular mechanisms of PML are poorly understood, PML has been shown to exhibit growth suppressor function (Mu et al., 1994; Koken et al., 1995; Liu et al., 1995; Le et al., 1996) and induce apoptosis through its RING domain (Borden et al., 1997) .
Molecular genetic techniques identify the PMLRARa fusion gene in nearly 100% of APL cases, although recently, rare cases lacking the t(15;17) have been characterized. Three variant APL translocations have been described, all of which involve translocations fusing RARa to partner genes other than PML. The t(11;17)(q23;q21) translocation, in which RARa is fused to the promyelocytic leukemia zinc ®nger gene (PLZF) (Chen et al., 1993) , appears to be the most commonly occurring variant (Licht et al., 1995) . It has been observed that ectopically expressed PLZF-RARa inhibits normal RARa function in a trans dominant fashion Licht et al., 1996) . Like PML-RARa, PLZF-RARa also appears to behave as a transcriptional repressor, capable of interacting with N-CoR and SMRT (Hong et al., 1997) . However, PLZF-RARa forms co-repressor complexes that are insensitive to pharmacological concentrations of RA (Grignani et al., 1998; Guidez et al., 1998; He et al., 1998; Lin et al., 1998) . Taken together, these data implicate PLZF-RARa in the pathogenesis of APL as well as characterize a molecular mechanism for the dierential response of APLs to RA. Recently, our group characterized a novel t(11;17)(q13;q21) variant APL translocation (Wells et al., 1996 (Wells et al., , 1997 which resulted in the fusion of RARa to the nuclear mitotic apparatus gene, NuMA (Lydersen and Pettijohn, 1980; Sparks et al., 1993) . A variant t(5;17)(q35;q21) APL translocation, which fuses RARa to the nucleophosmin gene (NPM) (Kang et al., 1974; Chan et al., 1989) has also been recently identi®ed (Redner et al., 1996) . Like PML-RARa and PLZF-RARa chimeric proteins, it appears that NPM-RARa shares the ability to act as a ligand-dependent transcriptional activator of retinoic acid responsive genes, in vitro (Redner et al., 1996) .
NPM is a nuclear matrix phosphoprotein that is ubiquitously expressed, and primarily localizes to the dense ®brillar and granular components of the nucleolus where it is believed to participate in ribosome assembly (Borer et al., 1989; Chan et al., 1990) . NPM also appears to interact speci®cally with proteins bearing nuclear/nucleolar localization signals , which is consistent with the proposal that NPM shuttles proteins destined for the nucleolus (Borer et al., 1989) . The NPM protein has a modular structure with four main functional motifs: a ribonuclease domain, a multimerization domain, a dimerization domain, and a DNA/RNA binding domain Herrera et al., 1995 Herrera et al., , 1996 . Interestingly, NPM rearrangements have been reported in speci®c translocations associated with hematological malignancies other than APL. Approximately one third of anaplastic large cell lymphoma (ALCL) tumors have a t(2;5)(p23;q35) translocation that fuses NPM to a novel transmembrane tyrosine-speci®c protein kinase, anaplastic lymphoma kinase (ALK) (Morris et al., 1994; Downing et al., 1995) . Similarly, cases of myelodysplastic syndrome and a subset of acute myeloid leukemia have been shown to be associated with a t(3;5)(q25;q34) translocation that fuses NPM to a novel myelodysplasia/myeloid leukemia factor (MLF1) (Yoneda-Kato et al., 1996) .
We describe the molecular characterization of a t(5;17) variant APL translocation involving NPM, and explore the eects NPM-RARa has on the subcellular localization of PML, RXRa, NPM, and PLZF in the bone marrow cells of a t(5;17) bearing patient.
Results

A variant APL translocation
All cells examined by cytogenetics revealed a complex karyotype that included a variant APL translocation involving chromosomes 5 and 17. The karyotype was 47, XY, t(5;17)(q35;q21), der (8)(p23), der(10)(q26), del(12)(q13q22), del(13)(q12q14), 716, 718, +21, +22 and +M. The t(15;17)(q22;q21) translocation was not detected in any of the metaphases examined. Southern blot analysis was performed to con®rm the molecular involvement of RARa, as well as to detect any occult rearrangement of PML. In patient DNA, additional restriction fragments were detected using the RARa speci®c LCN4A3B probe when compared to non-leukemic cells (Figure 1a) . No evidence of PML rearrangement was detected using overlapping PML cDNA probes. The t(5;17) translocation fuses nucleophosmin to RARa When study of the t(5;17) APL translocation began, the identity of the RARa fusion partner was unknown. Due to limited patient material, somatic cell hybrid lines were established and screened for the retention of one of the derivative chromosomes. Through cytogenetic and Southern analyses, we identi®ed a somatic cell hybrid that had retained the derivative 17 chromosome (data not shown). Northern blot analysis of this cell line, named A6, further revealed the presence of an aberrant 1.8 kb RARa mRNA ( Figure  1b) . Following a report that demonstrated an NPMRARa fusion event in a similar t(5;17) APL case (Redner et al., 1996) , the presence of a reciprocal RARa-NPM mRNA in somatic cell hybrid A6 was con®rmed by RT ± PCR analysis (data not shown).
t(5;17) APL blasts express NPM-RARa and RARa-NPM mRNA
The above results prompted us to examine patient RNA through a semi-nested RT ± PCR approach ( Figure 2a ) designed to detect NPM-RARa and RARa-NPM fusion mRNA. Independent reactions containing RARa primers R231 and R361, and NPM primers N96 and N1180 routinely detected normal RARa (130 bp) and NPM (1084 bp) mRNA. The NPM-RARa primer N96 with R361 and R724 produced a 429 bp fragment, while the RARa-NPM primers R231 and R254 with N1180 produced a 733 bp fragment. In addition, smaller 150 bp and 250 bp fragments were ampli®ed in both NPM-RARa and RARa-NPM reactions, respectively ( Figure 2b ). Sequence analysis indicated that the 429 bp NPM-RARa fragment was the product of a fusion event between NPM nucleotide 445 and RARa nucleotide 282 ( Figure  3a ). In addition, we found that the 733 bp RARa-NPM fragment was identical to that derived from the somatic cell hybrid A6 (Figure 3b ). Sequences from both of the smaller RT ± PCR products revealed that they were PCR artifacts.
NPM-RARa and RARa-NPM sequences predict modular proteins
The NPM breakpoint in this patient occurred between nucleotides 445 ± 446 of the NPM cDNA (amino acids 118 ± 119), while RARa was disrupted between nucleotides 280 and 281 (amino acids 59 ± 60). cDNA sequence analysis of the NPM-RARa and RARa-NPM breakpoint junctions revealed that the NPM junction was identical to previously reported NPM-ALK, and the short isoform of NPM-RARa (NPM sRARa) (Morris et al., 1994; Redner et al., 1996) (Figure 3a and b). The long isoform of NPM-RARa (NPM L -RARa) observed by Redner and colleagues was not expressed in our patient. We also noted that the NPM-RARa and reciprocal RARa-NPM cDNA sequences maintained intact opening reading frames capable of encoding 52 and 24 kd proteins, respectively. From these sequence data we were able to determine that the NPM-RARa protein would consist of the ribonuclease and multimerization domains of NPM joined to the DNA-binding, ligand-binding and dimerization domains of RARa. Conversely, RARa-NPM would consist of the cell/promoter speci®c transactivating domain of RARa joined to the dimerization and nucleic acid-binding domains of NPM (Figure 4 ).
PML localizes to intact nuclear bodies
Immuno¯uorescent confocal microscopy of U937 and NB4 control cells, treated with PML antibody, resulted in the expected localization patterns. Figure  5 shows that in U937 cells, PML localized to the nuclear matrix in 10 ± 20 distinct nuclear bodies or PODS. In NB4 cells, distinct nuclear bodies were a b Figure 2 (a) Schematic of the speci®c intron/exon structure of RARa and NPM. The NPM-RARa and RARa-NPM fusion genes are also shown. Coding regions are represented by shaded boxes while the white boxes denote untranslated regions. RT ± PCR primers (arrows) are labeled and are positioned under the exons from which they were generated. Dashed lines indicate alternative splicing patterns. (b) RT ± PCR analysis of cDNA prepared from patient bone marrow cells demonstrating the expression of NPMRARa and RARa-NPM mRNA. Reagent (R) and reverse transcriptase minus (RT7) controls containing all primer pairs tested are also shown. The expression of NPM and RARa is shown in lanes 1 and 2, respectively. The expression of NPMRARa and RARa-NPM is shown in lanes 3 and 4, respectively absent and PML was found in a dispersed, microspeckled pattern. In contrast to the pattern seen in NB4, PML localized to the nuclear matrix in distinct nuclear bodies in bone marrow cells analysed from the t(5;17) patient.
Nucleolar localization of NPM is disrupted
Immuno¯uorescent confocal microscopy of U937 control cells, treated with the NPM antibody, showed that NPM localized speci®cally to the nucleolus. While it was shown that NPM may not be exclusively nucleolar, we noted that in these control cells the majority of NPM was localized to the nucleolus in 1 ± 5 discreet dots (Figure 6 ). Nucleolar NPM localization was also con®rmed in normal, human bone marrow (data not shown). In contrast, the nucleolar localization of NPM was disrupted in t(5;17) cells analysed from the patient. In these cells, NPM was delocalized in a dispersed nuclear pattern (Figure 6 ).
PLZF expression is upregulated in t(5;17) APL cells
Expression and nuclear localization patterns for PLZF in U937 and HL60 control cells were determined by immuno¯uorescent confocal microscopy. As shown in Figure 7 , PLZF antibody detected the normal microspeckled and dispersed nuclear pattern in HL60 cells, whereas in the U937 negative control, only background signals were observed. While normal cells present in the patient's marrow showed no PLZF expression, leukemic bone marrow cells analysed from the t(5;17) patient exhibited signi®cant expression of PLZF in a microspeckled and diuse pattern (Figure 7) . NPM, NPM-RARa, and RXRa co-localize in t(5;17) APL cells
As shown in Figure 6 , immuno¯uorescent confocal microscopy of U937 control cells treated with RARa antibody con®rmed a dispersed, nuclear localization pattern. Similar results were observed for RXRa. When t(5;17) patient cells were examined, no discernable change in RARa and RXRa localization was observed. However, slides containing t(5;17) patient cells dually treated with NPM and RARa, or NPM and RXRa antibodies revealed that NPM, RARa and RXRa signals co-localized. Since the C-terminal RARa antibody is capable of detecting NPM-RARa, these data are consistent with co-localization of NPM, NPM-RARa, and RXRa in a dispersed nuclear manner.
Discussion
We report the molecular characterization of a variant t(5;17) translocation observed in a pediatric case of APL. RT ± PCR analysis using NPM and RARa speci®c primers revealed that a fusion event between NPM and RARa had occurred in the t(5;17) patient. The NPM junctions were found to be identical in sequence to the previously reported NPM-ALK junction sequences observed in ALCL (Morris et al., 1994; Downing et al., 1995) . In contrast to the Redner report, we identi®ed only one NPM-RARa isoform with an NPM junction sequence consistent with NPM sRARa. Similar to the Redner case, we observed the expression of the reciprocal RARa-NPM mRNA which was found to contain the N-terminal RARa transactivating domain juxtaposed to the NPM dimerization and DNA/RNA binding domains. It is of interest that RARa-PLZF appears to be expressed in all t(11;17)(q23;q21) patients, and that it also contains the N-terminal RARa transactivating domain juxtaposed to a DNA binding domain. Since RARa-PLZF seems to play a role in APL pathogenesis by acting as a trans dominant activator of PLZF responsive genes (Li et al., 1997) ; Sitterlin et al., 1997) , it is possible that RARa-NPM might also act as a second, dominant interfering gene in t(5;17)-associated APL. In this study, as well as in the previous t(5;17) APL report, the N-terminal portion of NPM is joined to the essential functional domains of RARa. The same RARa domains are invariably joined to the Nterminal portions of PML, PLZF, and NuMA. In vitro studies have demonstrated that PML-RARa and PLZF-RARa disrupt the transactivating eects of RARa at the RAREb 2 promoter, and that the dominant negative eects of PML-RARa and PLZFRARa are reversed in the presence of ectopically expressed RXRa Licht et al., 1996) . PML-RARa and PLZF-RARa heterodimerize with RXRa through the RARa dimerization domain retained in the RARa portion of the fusions (Jansen et al., 1995; Licht et al., 1996) . Recently it has been shown that both PML-RARa and PLZF-RARa silence the transcription of RA responsive genes under physiological concentrations of RA (Grignani et al., 1998; He et al., 1998; Lin et al., 1998) . In light of these studies, as well as the fact that RAR/RXR heterodimerization is required for RAR function Bugge et al., 1992; Zhang et al., 1992) , it is surprising that PML-RARa/RXRa heterodimers do not appear essential for PML-RARa's eect on dierentiation (Grignani et al., 1996) . Taken together, however, it appears that PML-RARa, PLZF-RARa, and possibly NPM-RARa disrupt wildtype RARa function by sequestering RXRa to co-repressor complexes. Our observations of co-localization of NPM-RARa and RXRa in t(5;17) blasts demonstrate that NPM-RARa may share the ability to sequester RXRa, and potentially disrupt RARa function.
In addition to the disruption of the retinoid signaling pathway, APL fusion genes may contribute to the disease phenotype by disrupting the normal functions of the partner genes. Mutation analysis of the PML portion of PML-RARa has shown that the PML multimerization domain is critical in promoting altered dierentiation in APL cells (Grignani et al., 1996) . The POZ domain of PLZF, which is also a functional multimerization domain (Bardwell and Treisman, 1994) , appears to be an essential component of PLZF-RARa that confers altered response to dierentiation signals . In addition, it has been demonstrated that PML and PLZF form heterodimers with PML-RARa and PLZF-RARa, respectively, through these multimerization domains (Perez et al., 1993; Licht et al., 1996; Dong et al., 1996) . Structural analysis of NPM-RARa indicates that the multimerization domain of NPM is retained in the chimeric protein. Our immuno¯uorescent confocal microscopy studies demonstrate that the nucleolar localization of NPM is disrupted in t(5;17) APL cells, and that NPM co-localizes with NPM-RARa in a dispersed nuclear pattern. These data suggest that NPM-RARa aects wildtype NPM in t(5;17) APL, and support the notion that chimeric RARa proteins in APL deregulate the wildtype function of the partner through a mechanism similar to that of RXRa sequestration.
In normal hematopoietic cells, PML localizes to the nuclear matrix in 10 ± 20 discreet nuclear bodies or PODS (Daniel et al., 1993; Dyck et al., 1994) . In t(15;17) APL cells, several groups have observed that the expression of PML-RARa delocalizes PML from U937 NB4 J700 Figure 5 Immuno¯uorescent confocal microscopy of control cell lines U937 and NB4 treated with a monoclonal PML antibody (FITC, green) . Note that in U937, PML is localized to 10 ± 20 nuclear bodies. t(15;17) bearing NB4 cells con®rmed that PML is dispersed throughout the nucleus. Analysis of bone marrow cells from the t(5;17) patient (J700) demonstrates that PML is localized to 10 ± 20 nuclear bodies, as in U937. White bars represent 10 mm these nuclear bodies in an RA dependent fashion (Dyck et al., 1994; Koken et al., 1994; Weis et al., 1994) . This has led to the proposal that PML nuclear body formation plays a role in the dierentiation response of myeloid progenitors to growth factors (Dyck et al., 1994) . Evidence that disruption of PML nuclear bodies may be an epiphenomenon associated speci®cally with t(15;17) APL is seen in t(11;17) APL cells expressing PLZF-RARa (Grimwade et al., 1997) or NuMA-RARa (Wells et al., 1997) . In these cells immuno¯uorescent confocal microscopy reveals that PML localizes normally to discreet nuclear bodies. We con®rm these ®ndings in t(5;17) APL cells expressing NPM-RARa, where PML nuclear bodies are also intact. Thus, chimeric RARa proteins derived from variant APL translocations do not appear to aect PML localization, suggesting that APL pathogenesis is not dependent on delocalization of PML from the nuclear body structure. While the existence of a functional link between the RARa partner proteins has yet to be described, all four are nuclear matrix phosphoproteins with the capacity to form dimers or multimers. Recent data have demonstrated that PLZF expression is upregulated in U937 J700 J700 Figure 6 Immuno¯uorescent confocal microscopy of control cells U937 dually treated with a monoclonal NPM antibody (FITC) plus a polyclonal RARa antibody (TRITC, red), or dually treated with NPM (as above) plus a polyclonal RXRa antibody (TRITC). Note that in U937, NPM is localized to 1 ± 5 nucleolar dots, whereas RARa and RXRa are both dispersed throughout the nucleus. Analysis of bone marrow cells from the t(5;17) patient (J700) dually treated with NPM plus RARa/RXRa antibodies demonstrates that NPM localization is completely disrupted. Note that NPM, NPM-RARa and RXRa co-localize in a dispersed nuclear manner t(11;17)(q23;q21) and t(15;17) APL cells, and that the nuclear localization of PLZF is disrupted in these forms of APL as a direct result of PLZF/PLZF-RARa and PLZF/PML-RARa heterodimers, respectively (Koken et al., 1997) . Consistent with the above data we show that PLZF expression appears to be similarly upregulated in a microspeckled pattern in the nucleus of t(5;17) cells. Although speci®c interactions between NPM and PLZF remain to be proven, these data suggest that PLZF may play a more universal role in the pathogenesis of all forms of APL.
Even though the t(5;17) variant has only been identi®ed in a minority of APL patients, it may represent a distinct subtype of APL and a model system that can aid in the molecular study of APL pathogenesis. While it does not interfere with PML nuclear body formation, the expression of NPM-RARa in t(5;17) APL results in the co-localization of NPM, RXRa, and NPM-RARa. Moreover, PLZF expression is also aected, as it is observed in a microspeckled pattern in the nucleus of patient leukemic cells but not in patient normal bone marrow cells. In summary, our data provide further evidence that the molecular consequences of APL translocations are the deregulation of both the retinoid signaling pathway and endogenous translocation partner proteins. Furthermore, our data con®rm that APL pathogenesis is not dependent on the delocalization of PML from its nuclear bodies. Further characterization of the mechanisms of action of NPM-RARa should lead to a better understanding of normal hematopoiesis and its deregulation in APL.
Materials and methods
Case presentation
The patient, a 12 year-old male, presented with disseminated intravascular coagulation, and bilateral lower limb hematomas. Bone marrow examination revealed a hypercellular specimen that contained 470% promyelocytes. Auer rods were not detected. Few mature cells of the granulocytic series were present and cells of the erythroid lineage appeared dysplastic. Cells surface immunophenotype of the abnormal cells was determined by¯ow cytometry to be HLA-DR7, CD13+, CD147, CD33+. A diagnosis of acute myelogenous leukemia subtype M3v was made, and remission induction chemotherapy (cytosine arabinoside [AraC] 100 mg/m 2 /day for 7 days and daunorubicin [DNR] 45 mg/m 2 /day for 3 days) was followed by consolidation chemotherapy that combined DNR, AraC, 6-thioguanine, etoposide, and dexamethasone. A bone marrow sample taken after the ®rst consolidation cycle revealed morphological and cytogenetic remission, however, a follow-up specimen (5 months post-diagnosis) showed evidence of relapse. Re-induction therapy consisted of AraC and atRA (25 mg/m 2 /day). Cytogenetic remission was documented 5 weeks post-induction, and maintenance therapy with atRA (45 mg/m 2 /day) was administered for 2 months leading up to bone marrow transplantation. The patient underwent allogeneic bone marrow transplantation from a matched sibling donor 13 weeks after re-induction. While patient response to atRA alone is dicult to assess since AraC was part of the re-induction treatment, the dierentiation eects of atRA probably contributed to this patient's remission status prior to transplantation. Consistent with this, Redner and colleagues have recently demonstrated that in short term culture systems, cells bearing the t(5;17) translocation terminally dierentiate in response to retinoic acid (Redner et al., 1997) .
Somatic cell hybrids
A panel of somatic cell hybrids was produced using PEG fusion (Davidson et al., 1976; Norwood et al., 1976) , and screened to identify patient/CHO hybrid clones bearing derivative t(5;17) chromosomes. The parental cells used to construct these hybrids were patient marrow cells, and the MEV-1, ADE-B mutant CHO cell lines. 25 MEV-1 hybrids (M1 ± M25) were selected for the presence of the short arm of chromosome 5 (3-hydroxy-3-methylglutaryl-coenzyme A synthase), hence, the patient derivative 5 chromosome. Ten ADE-B hybrids (A1 ± A10) were selected for the presence of the short arm of human chromosome 17 (5-bromodeoxyuridine), hence, the patient derivative 17 chromosome. Thirty-four hybrid lines were successfully maintained in Ham's F12 media and harvested for cytogenetic, Southern, RT ± PCR and Northern analyses.
Southern blotting
Standard phenol-chloroform techniques were applied to genomic DNA from 1610 7 fresh/cryopreserved patient mononuclear cells, and somatic cell hybrid lines. Restric-
U937
HL60 J700 Figure 7 Immuno¯uorescent confocal microscopy of U937 and HL60 control cells, and bone marrow cells from the t(5;17) patient (J700) treated with a monoclonal PLZF antibody (FITC). U937 cells show no PLZF expression (background), whereas in HL60, PLZF is localized both in a microspeckled and dispersed nuclear pattern. Analysis of patient leukemic cells demonstrates that PLZF is expressed in a microspeckled pattern in the nucleus tion enzymes BamHI, PstI, and EcoRI were used independently and in combination to digest 10 mg samples of DNA. Standard Southern blotting techniques were used in these studies (Southern, 1975) . RARa involvement was determined by using a previously described genomic fragment LCN4A3B (Borrow et al., 1990) as a hybridization probe. Two overlapping PML cDNA probes, pAGH7 and pAGU3 (E Solomon, London, UK), were used to screen for occult PML rearrangements.
RT ± PCR
cDNA was reversed transcribed from sample RNA extracts for the purposes of PCR analyses. Total RNA (1 mg) was heated for 2 min at 658C to denature any secondary mRNA structure, and was reverse transcribed in 20 ml cDNA reactions containing 56 ®rst strand buer (50 mM Tris-HCl, pH=8.3, 75 mM KCl, 3 mM MgCl 2 , 10 mM DTT, 0.5 mM dNTP ®nal concentration), 100 ng of random hexamer, 20 units of RNA guard (Pharmacia, Baie d'UrfeÂ , QC), and 10 units of DNase I (BoehringerMannheim, Laval, QC). Primers were generated from RARa and NPM cDNA sequences retrieved from GENBANK to allow the ampli®cation of RARa (130 bp), NPM (1084 bp), as well as NPM-RARa (429 bp) and RARa-NPM (733 bp) mRNA species. 50 ml reactions (PCR buer made up of 2.5 mM MgCl 2 , 50 mM KCl, 10 mM TrisHCl pH=8.8, 0.01% gelatin, and 0.1% Triton X-100) were ampli®ed in a TRIO-Thermoblock thermocycler (Biometra, Tampa, FL, USA). The location of the following primers is shown in Figure 2a :
R231=5'-TCTCCAGCACCAGCTTCCAG-3' R254=5'-GTGGATATAGCACACCATCC-3' R361=5'-GCTTGTAGATGCGGGGTAG-3' R724=5'-ATTTGCCCAGCTGGCAGAGG-3' N96=5'-GGAAGATTCGATGGACATGG-3' N1180=5'-CAAGCAAAGGGTGGAGTTCC-3'
Cloning and sequencing RT ± PCR products were puri®ed from low melting point agarose gels, concentrated in a microconcentrator (Amicon, Beverly, MA, USA), and cloned directly into the SrfI restriction site of the pCR-SCRIPT TM vector (Stratagene, La Jolla, CA, USA). Highly concentrated, pure plasmid DNA was isolated from positive clones using standard alkaline-lysis mini-preparation techniques and sequenced using a Sequenase DNA Sequencing kit (USB-Cleveland, OH, USA) according to the manufacturer's protocol for double stranded plasmid DNA templates. Sequenced samples were analysed on a 6% urea-polyacrylamide gel prepared using Long Ranger Gel Solution Concentrate (JT Baker, Phillipsburg, NJ, USA), and screened against GENBANK for high percentage sequence matches.
Immuno¯uorescent confocal microscopy APES-coated, glass microscope slides were prepared for the t(15;17) APL cell line NB4 (M Lanotte, INSERM, Paris, France), the myeloid progenitor cell line U937 (ATCC, Rockville, MD, USA), the promyelocytic cell line HL60 (ATCC, Rockville, MD, USA), and t(5;17) APL patient bone marrow cells. Samples were spread at medium density, ®xed for 2 min at 7108C in 1:1 methanol : acetone and allowed to air-dry for 20 min. Slides were blocked with 3% pre-immune goat serum in PN buer (0.1 M Na 2 HPO 4 /NaH 2 PO 4 , Tween 20) for 1 h at 378C. After two PN buer washes, slides were incubated for 2 h at 378C with dilutions of RARa, RXRa, PML (Oncogene Science, Cambridge, MA, USA), NPM (S Morris, Memphis, TN, USA), and PLZF antibodies (J Licht, New York, NY, USA) in PN buer. Polyclonal antibodies were used against RARa and RXRa, whereas monoclonal antibodies were used against PML, NPM, and PLZF. Texas red-conjugated goat anti-rabbit (Santa Cruz Biotech, Santa Cruz, CA, USA) or FITC-conjugated goat anti-mouse (Oncogene Science) secondary antibodies were then added and incubated for 1 h at 378C. After a ®nal rinse in PN buer, slides were mounted in vectashield antifade (Vector, Burlingame, CA, USA), and cells were viewed on a laser scanning confocal microscope (Zeiss, Hospital for Sick Children, Toronto, Canada).
